MTOR and lung cancer: Our study suggests a pathway differs from mTOR cascade in that EGFRhigh lung cancer cells survive Met with sustained phosphorylation of EGFR in response to EGF, and increased sensitivity to Erlo, one of the most wildly used EGFR-TKIs at present in the clinic.